LivaNova (NASDAQ:LIVN) Given New $56.00 Price Target at Barclays

LivaNova (NASDAQ:LIVN) had its price objective cut by Barclays from $58.00 to $56.00 in a report released on Friday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Several other research analysts have also recently issued reports on the company. Mizuho dropped their price target on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Needham & Company LLC cut their target price on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Stifel Nicolaus cut their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group lowered their price target on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $61.17.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $39.17 on Friday. LivaNova has a 12 month low of $38.91 and a 12 month high of $64.47. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of 93.26 and a beta of 1.10. The stock’s 50 day moving average price is $46.79 and its 200 day moving average price is $49.32. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Insider Activity

In related news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.27% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LivaNova

A number of large investors have recently bought and sold shares of LIVN. Point72 Asset Management L.P. boosted its holdings in LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after purchasing an additional 806,374 shares in the last quarter. Freestone Grove Partners LP bought a new stake in LivaNova in the fourth quarter worth $23,102,000. Artisan Partners Limited Partnership bought a new stake in LivaNova in the fourth quarter worth $21,340,000. The Manufacturers Life Insurance Company boosted its holdings in LivaNova by 163.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company’s stock worth $25,303,000 after purchasing an additional 339,139 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in LivaNova by 79.3% in the fourth quarter. AQR Capital Management LLC now owns 742,180 shares of the company’s stock worth $34,214,000 after purchasing an additional 328,313 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.